Company intelligence / Profile preview

Space LiinTech

Daejeon, South Korea

Ownership: Private
Development stage: Other

Overview

Space LiinTech recently launched 'BEE-PC1,' Korea's first automated space medicine research module for protein crystallization in microgravity on the ISS. Initial experiments target high-purity protein crystals for future therapeutic discovery, with clinical-stage programs not yet reported. Company intends to offer commercial services starting in 2027, based on pilot results and ongoing development partnerships with KIST and Harvard Medical School.

Therapeutic areas: OtherRare Diseases
Modalities: ProteinCell therapyBiologic
Industry: Drug Discovery Services

Partnerships

Korea Institute of Science and Technology (KIST)Harvard Medical SchoolINNOSPACEIntergravity TechnologiesVoyager Technologies (George Washington Carver Science Park at Ohio State University)

Beyond the preview

Go deeper on Space LiinTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Space LiinTech.

Explore the full profile